Literature DB >> 11334945

Alternative versus classical macrophage activation during experimental African trypanosomosis.

P D Baetselier1, B Namangala, W Noël, L Brys, E Pays, A Beschin.   

Abstract

African trypanosomes are extracellular parasites causing sleeping sickness to human or nagana to livestock in sub-Saharan Africa. To gain insight into factors governing resistance/susceptibility to these parasites, the immune responses in mice infected with a Trypanosoma brucei phospholipase C null mutant (PLC(-/-)) or its wild type counterpart (WT) were compared. We found that the T. b. brucei mutant inducing a chronic infection triggers the production of type I cytokines during the early stage of infection, followed by the secretion of type II cytokines in the late/chronic phase of the disease. In contrast, WT-infected mice are killed within 5 weeks and remain locked in a type I cytokine response. The type I/type II cytokine balance may influence the development of different subsets of suppressive macrophages, i.e. classically activated macrophages (type I) versus alternatively activated macrophages (type II) that are antagonistically regulated. Therefore, the phenotype and accessory cell function of macrophages elicited during WT and PLC(-/-) T. b. brucei infections were addressed. Results indicate that classically activated macrophages develop in a type I cytokine environment in the early phase of both WT and PLC(-/-) trypanosome infections. In the late stage of infection, only PLC(-/-)-infected mice resisting the infection develop type II cytokine-associated alternative macrophages. In parallel, we found that mice susceptible to Trypanosoma congolense infection, showing an exponential parasite growth until they die, have a higher level of type II cytokines in the early stage of infection than resistant animals controlling the first peak of parasitaemia. The levels of type I cytokines were comparable in both T. congolense-resistant and -susceptible mice. On the basis of these results, we propose that survival to African trypanosome infection requires a type I cytokine environment and classical macrophage activation in the early stage of infection, enabling mice to control the first peak of parasitaemia. Thereafter, a switch to type II cytokine environment triggering alternative macrophage activation is required to enable progression of the disease into the chronic phase. The possible role of the sequential activation of alternative macrophages in the late/chronic stage of infection in the increased resistance of mice to PLC(-/-) T. b. brucei will be discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334945     DOI: 10.1016/s0020-7519(01)00170-9

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  24 in total

1.  Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis.

Authors:  Claudia Manca; Michael B Reed; Sherry Freeman; Barun Mathema; Barry Kreiswirth; Clifton E Barry; Gilla Kaplan
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 2.  Host-parasite interactions in trypanosomiasis: on the way to an antidisease strategy.

Authors:  Nicolas Antoine-Moussiaux; Philippe Büscher; Daniel Desmecht
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

3.  Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation.

Authors:  A Guerrero; N Jain; X Wang; B C Fries
Journal:  Infect Immun       Date:  2010-01-04       Impact factor: 3.441

4.  Infection with arginase-deficient Leishmania major reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis.

Authors:  Helen M Muleme; Rosa M Reguera; Alicia Berard; Richard Azinwi; Ping Jia; Ifeoma B Okwor; Stephen Beverley; Jude E Uzonna
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals.

Authors:  Cinthia C Stempin; Laura R Dulgerian; Vanina V Garrido; Fabio M Cerban
Journal:  J Biomed Biotechnol       Date:  2009-12-09

6.  Immunobiology of African trypanosomes: need of alternative interventions.

Authors:  Toya Nath Baral
Journal:  J Biomed Biotechnol       Date:  2010-02-23

Review 7.  Impact of infection on transplantation tolerance.

Authors:  Shuangjin Yu; Chang Su; Xunrong Luo
Journal:  Immunol Rev       Date:  2019-09-19       Impact factor: 12.988

8.  Gene expression profiling in a mouse model for African trypanosomiasis.

Authors:  S Kierstein; H Noyes; J Naessens; Y Nakamura; C Pritchard; J Gibson; S Kemp; A Brass
Journal:  Genes Immun       Date:  2006-10-26       Impact factor: 2.676

9.  Cerebral and peripheral changes occurring in nitric oxide (NO) synthesis in a rat model of sleeping sickness: identification of brain iNOS expressing cells.

Authors:  Donia Amrouni; Sabine Gautier-Sauvigné; Anne Meiller; Philippe Vincendeau; Bernard Bouteille; Alain Buguet; Raymond Cespuglio
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

10.  Immunophenotypic lymphocyte profiles in human african trypanosomiasis.

Authors:  Caroline Boda; Bertrand Courtioux; Pierre Roques; Lynda Pervieux; Gédéon Vatunga; Théophile Josenando; Constant Roger Ayenengoye; Bernard Bouteille; Marie-Odile Jauberteau; Sylvie Bisser
Journal:  PLoS One       Date:  2009-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.